Showing 6871-6880 of 9462 results for "".
- Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and AD in Four Additional Countrieshttps://practicaldermatology.com/news/galderma-receives-filing-acceptances-nemolizumab-prurigo-nodularis-and-ad-four-additional-countries/2462968/
- Mechanical Micro-Coring Shows Promise for Neck Treatmenthttps://practicaldermatology.com/news/aslms-2024-mechanical-micro-coring-shows-promise-neck-treatment/2462716/Mechanical dermal micro-coring is a safe and effective option for improving skin laxity, texture, and wrinkles on the neck, based on new data appearing at the American Society for Laser Medicine and Surgery (ASLMS) 43rd Annual Conference on Energy-based Medicine and Science in Baltimor
- Deucravacitinib Shows Sustained Response, Safety Profile: Analyseshttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-response-safety-profile-analyses/2462221/Deucravacitinib (SOTYKTU, Bristol Myers Squibb) is a first-in-class, oral, selective allosteric TYK2 inhibitor, and has been approved in the United States, European Union, and other countries for use in adults with mode
- Revealed: How Chronological Aging Affects EV Production by Human Keratinocyteshttps://practicaldermatology.com/news/revealed-how-chronological-aging-affects-ev-production-by-human-keratinocytes/2462166/Aging modulates extracellular vesicles of epidermal keratinocytes, new research in Aging suggests. The disturbance of intercellular communication is one of the hallmarks of aging. In their new study, researchers from
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers i
- Sotyktu Demonstrates Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque PsOhttps://practicaldermatology.com/news/sotyktu-demonstrates-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-pso/2462066/Bristol Myers Squibb’s
- AD Pipeline Update: FDA Rejects Lilly’s Lebrikizumab Due to Third-Party Manufacturing Issueshttps://practicaldermatology.com/news/ad-pipeline-update-fda-rejects-lillys-lebrikizumab-due-to-third-party-manufacturing-issues/2462037/The U.S. Food and Drug Administration (FDA) did not approve Eli Lilly's lebrikizumab biologic license application (BLA) for the treatment of moderate-to-severe atopic dermatitis due to findings during an inspection of a contract manufacturer. The letter cited findings
- Wound Repair Breakthrough: Protein Coacervates Engineered Into Adhesive for “Unprecedented” Skin Repair Speedhttps://practicaldermatology.com/news/wound-repair-breakthrough-protein-coacervates-engineered-into-adhesive-for-unprecedented-skin-repair-speed/2462032/A team of researchers from China is developing a novel biocomposite adhesive that may revolutionize wound management and tissue repair, according to a study in Engineering.
- Arcutis Launches Educational Campaign for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-educational-campaign-for-people-living-with-seborrheic-dermatitis/2462021/Arcutis Biotherapeutics, Inc. is launching
- Houston Dermatologist Rolls Out New Class of Topical Pain Relievershttps://practicaldermatology.com/news/houston-dermatologist-rolls-out-new-class-of-topical-pain-relievers/2461974/Milton D. Moore, MD, a dermatologist and founder & CEO of Moore Unique Skin Care, LLC and